chlortalidone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	625	77-36-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: clortalidone phthalamudine chlorphthalidolone chlorthalidone chlorthalidon chlortalidone	A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic. Molecular weight: 338.76 Formula: C14H11ClN2O4S CLOGP: 0.45 LIPINSKI: 0 HAC: 6 HDO: 3 TPSA: 109.49 ALOGS: -3.81 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

clortalidone
phthalamudine
chlorphthalidolone
chlorthalidone
chlorthalidon
chlortalidone

A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.

Molecular weight: 338.76
Formula: C14H11ClN2O4S
CLOGP: 0.45
LIPINSKI: 0
HAC: 6
HDO: 3
TPSA: 109.49
ALOGS: -3.81
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
25	mg	O
25	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	4	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.12 mg/mL	Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine)	65 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	2.46 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	3.90 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1.50 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.24 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	36 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
April 7, 1960	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyponatraemia	154.53	13.97	142	11436	111758	63365686
Hypokalaemia	61.78	13.97	85	11493	103719	63373725
Pneumonia viral	59.46	13.97	29	11549	7893	63469551
Cardiac murmur	52.87	13.97	33	11545	14519	63462925
Presyncope	51.95	13.97	42	11536	27743	63449701
Blood pressure increased	49.24	13.97	98	11480	161964	63315480
Breath sounds abnormal	47.91	13.97	28	11550	10945	63466499
Systemic infection	37.82	13.97	18	11560	4642	63472802
Milk-alkali syndrome	36.33	13.97	11	11567	817	63476627
Myxoedema coma	33.67	13.97	9	11569	426	63477018
Poor personal hygiene	31.13	13.97	8	11570	324	63477120
Wheezing	30.44	13.97	59	11519	95536	63381908
Eosinophilia	29.63	13.97	28	11550	22728	63454716
Diarrhoea infectious	29.20	13.97	10	11568	1101	63476343
Angle closure glaucoma	29.09	13.97	12	11566	2207	63475237
Nasal congestion	27.94	13.97	46	11532	65614	63411830
Chronic obstructive pulmonary disease	26.78	13.97	44	11534	62642	63414802
Renal impairment	26.28	13.97	53	11525	88302	63389142
Blood potassium decreased	25.86	13.97	35	11543	41991	63435453
Hyperlactacidaemia	23.10	13.97	11	11567	2838	63474606
Catastrophic reaction	22.81	13.97	4	11574	23	63477421
Synovitis	21.56	13.97	4	11574	186914	63290530
Treatment failure	21.43	13.97	5	11573	199038	63278406
Joint abscess	20.36	13.97	6	11572	406	63477038
Asthma	20.17	13.97	60	11518	127501	63349943
Strabismus	20.16	13.97	9	11569	2005	63475439
Cockroach allergy	19.30	13.97	4	11574	61	63477383
Blood glucose increased	18.94	13.97	45	11533	83711	63393733
Upper respiratory tract infection	18.46	13.97	44	11534	82003	63395441
Nodal rhythm	18.13	13.97	8	11570	1735	63475709
Productive cough	17.71	13.97	37	11541	63171	63414273
Toxicity to various agents	17.25	13.97	12	11566	247238	63230206
Abdominal discomfort	17.11	13.97	20	11558	320865	63156579
Drug interaction	16.52	13.97	84	11494	229047	63248397
Discomfort	16.51	13.97	5	11573	167369	63310075
Oedema peripheral	16.21	13.97	73	11505	189438	63288006
Systemic lupus erythematosus	16.15	13.97	9	11569	208909	63268535
Contraindicated product administered	15.94	13.97	10	11568	217638	63259806
Peripheral swelling	15.49	13.97	92	11486	265850	63211594
Hepatic enzyme increased	15.23	13.97	9	11569	202319	63275125
Hypervitaminosis	15.07	13.97	3	11575	37	63477407
Cough	15	13.97	98	11480	292645	63184799
Anaemia of malignant disease	14.78	13.97	5	11573	530	63476914
Drug intolerance	14.64	13.97	21	11557	308640	63168804
Iron deficiency anaemia	14.41	13.97	18	11560	19951	63457493
Renal artery stenosis	14.36	13.97	7	11571	1902	63475542

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Meningitis aseptic	108.93	16.80	37	7906	3187	34945801
Renal artery stenosis	96.67	16.80	31	7912	2230	34946758
Hyponatraemia	94.93	16.80	105	7838	82586	34866402
Rectal prolapse	94.35	16.80	22	7921	470	34948518
Renal cyst haemorrhage	88.63	16.80	22	7921	617	34948371
Intraductal papillary mucinous neoplasm	82.21	16.80	20	7923	515	34948473
SARS-CoV-2 antibody test positive	81.52	16.80	19	7924	405	34948583
Hypokalaemia	79.30	16.80	81	7862	58133	34890855
Abdominal wall haemorrhage	73.67	16.80	18	7925	472	34948516
Vena cava injury	69.43	16.80	16	7927	324	34948664
Carotid arteriosclerosis	65.43	16.80	22	7921	1836	34947152
Delayed graft function	61.58	16.80	22	7921	2199	34946789
Vascular anastomotic haemorrhage	61.25	16.80	14	7929	273	34948715
Perineal cyst	56.61	16.80	13	7930	259	34948729
Aortic dilatation	54.97	16.80	18	7925	1383	34947605
Mean cell volume increased	53.98	16.80	22	7921	3147	34945841
Hyperparathyroidism secondary	52.98	16.80	18	7925	1550	34947438
Vascular compression	52.42	16.80	13	7930	363	34948625
Actinic keratosis	49.33	16.80	23	7920	4544	34944444
Aortic arteriosclerosis	49.00	16.80	23	7920	4613	34944375
Diverticulum intestinal	48.93	16.80	22	7921	3999	34944989
Hepatosplenomegaly	48.17	16.80	22	7921	4147	34944841
Left ventricular hypertrophy	47.30	16.80	27	7916	8103	34940885
Intervertebral disc space narrowing	47.30	16.80	15	7928	1040	34947948
Chronic kidney disease	46.63	16.80	52	7891	41158	34907830
Choroidal effusion	44.35	16.80	10	7933	183	34948805
Fibrillary glomerulonephritis	43.86	16.80	8	7935	46	34948942
Spinal stenosis	43.27	16.80	22	7921	5247	34943741
Restless legs syndrome	41.38	16.80	25	7918	8329	34940659
Blood 25-hydroxycholecalciferol decreased	41.04	16.80	10	7933	259	34948729
Spinal osteoarthritis	40.68	16.80	24	7919	7659	34941329
Glycosylated haemoglobin increased	39.00	16.80	27	7916	11333	34937655
Swelling of eyelid	38.50	16.80	13	7930	1098	34947890
Presyncope	38.40	16.80	33	7910	19026	34929962
Activated partial thromboplastin time prolonged	35.46	16.80	23	7920	8672	34940316
Hepatic steatosis	35.39	16.80	31	7912	18331	34930657
Blood potassium increased	34.12	16.80	29	7914	16466	34932522
Vitamin D decreased	32.94	16.80	16	7927	3460	34945528
Arteriosclerosis	31.01	16.80	24	7919	11944	34937044
Haemorrhoids	30.92	16.80	26	7917	14549	34934439
Squamous cell carcinoma of skin	30.80	16.80	23	7920	10858	34938130
Dizziness	29.01	16.80	112	7831	218409	34730579
Bradycardia	28.74	16.80	57	7886	75361	34873627
Atrioventricular block first degree	27.04	16.80	17	7926	6075	34942913
Benign prostatic hyperplasia	26.99	16.80	24	7919	14471	34934517
Complications of transplanted kidney	23.36	16.80	14	7929	4595	34944393
Basal cell carcinoma	22.55	16.80	25	7918	19633	34929355
Blood pressure fluctuation	22.16	16.80	28	7915	25221	34923767
Vertigo	21.90	16.80	28	7915	25508	34923480
Hemiparaesthesia	21.39	16.80	5	7938	108	34948880
Gastrooesophageal reflux disease	21.33	16.80	34	7909	37890	34911098
Fear	20.81	16.80	18	7925	10458	34938530
Aortic valve incompetence	20.19	16.80	14	7929	5890	34943098
Red blood cell count decreased	19.06	16.80	28	7915	29062	34919926
Choroidal detachment	18.92	16.80	6	7937	416	34948572
Renal cyst	18.83	16.80	16	7927	9077	34939911
Incorrect dose administered	18.37	16.80	33	7910	40482	34908506
Amyloidosis	17.82	16.80	9	7934	2114	34946874
Angle closure glaucoma	17.52	16.80	7	7936	950	34948038

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyponatraemia	244.26	13.47	238	16268	177610	79550272
Hypokalaemia	116.16	13.47	146	16360	143894	79583988
Renal artery stenosis	109.48	13.47	37	16469	3445	79724437
Presyncope	94.78	13.47	74	16432	40980	79686902
Renal cyst haemorrhage	88.91	13.47	22	16484	670	79727212
SARS-CoV-2 antibody test positive	82.62	13.47	19	16487	420	79727462
Intraductal papillary mucinous neoplasm	76.11	13.47	20	16486	778	79727104
Vena cava injury	70.35	13.47	16	16490	336	79727546
Abdominal wall haemorrhage	69.11	13.47	18	16488	676	79727206
Rectal prolapse	64.00	13.47	22	16484	2156	79725726
Vascular anastomotic haemorrhage	62.54	13.47	14	16492	273	79727609
Carotid arteriosclerosis	59.73	13.47	22	16484	2634	79725248
Perineal cyst	57.95	13.47	13	16493	256	79727626
Delayed graft function	53.79	13.47	22	16484	3485	79724397
Aortic dilatation	52.06	13.47	18	16488	1794	79726088
Pneumonia viral	52.02	13.47	29	16477	9129	79718753
Left ventricular hypertrophy	49.18	13.47	30	16476	11161	79716721
Chronic kidney disease	48.46	13.47	64	16442	66090	79661792
Vascular compression	48.16	13.47	13	16493	561	79727321
Angle closure glaucoma	46.78	13.47	19	16487	2957	79724925
Cardiac murmur	46.54	13.47	33	16473	15791	79712091
Hyperparathyroidism secondary	45.33	13.47	18	16488	2642	79725240
Intervertebral disc space narrowing	45.11	13.47	16	16490	1719	79726163
Mean cell volume increased	44.49	13.47	23	16483	6230	79721652
Fibrillary glomerulonephritis	43.37	13.47	8	16498	55	79727827
Actinic keratosis	42.35	13.47	22	16484	6020	79721862
Hepatosplenomegaly	42.25	13.47	22	16484	6047	79721835
Aortic arteriosclerosis	42.01	13.47	25	16481	8893	79718989
Choroidal effusion	41.55	13.47	12	16494	665	79727217
Bradycardia	40.76	13.47	88	16418	135469	79592413
Blood 25-hydroxycholecalciferol decreased	38.30	13.47	10	16496	379	79727503
Diverticulum intestinal	37.64	13.47	23	16483	8582	79719300
Blood pressure increased	37.18	13.47	112	16394	211248	79516634
Blood potassium increased	36.03	13.47	37	16469	29238	79698644
Breath sounds abnormal	35.13	13.47	28	16478	15956	79711926
Arteriosclerosis	33.94	13.47	29	16477	18198	79709684
Glycosylated haemoglobin increased	32.55	13.47	29	16477	19231	79708651
Squamous cell carcinoma of skin	31.73	13.47	25	16481	14008	79713874
Spinal osteoarthritis	31.66	13.47	27	16479	16900	79710982
Hepatic steatosis	31.55	13.47	39	16467	37699	79690183
Benign prostatic hyperplasia	31.36	13.47	23	16483	11589	79716293
Oedema peripheral	30.55	13.47	118	16388	252170	79475712
Blood potassium decreased	29.53	13.47	42	16464	46470	79681412
Activated partial thromboplastin time prolonged	29.31	13.47	24	16482	14204	79713678
Milk-alkali syndrome	29.14	13.47	11	16495	1409	79726473
Meningitis aseptic	28.98	13.47	18	16488	6910	79720972
Myxoedema coma	27.85	13.47	9	16497	728	79727154
Renal impairment	27.15	13.47	83	16423	157700	79570182
Spinal stenosis	27.13	13.47	24	16482	15767	79712115
Dizziness	26.51	13.47	193	16313	526248	79201634
Poor personal hygiene	26.22	13.47	8	16498	536	79727346
Basal cell carcinoma	25.59	13.47	35	16471	37340	79690542
Syncope	25.13	13.47	88	16418	179361	79548521
Swelling of eyelid	24.22	13.47	13	16493	3798	79724084
Diarrhoea infectious	23.97	13.47	10	16496	1664	79726218
Vitamin D decreased	23.46	13.47	18	16488	9707	79718175
Systemic infection	23.41	13.47	18	16488	9734	79718148
Nasal congestion	23.34	13.47	50	16456	76502	79651380
Catastrophic reaction	22.30	13.47	4	16502	23	79727859
Restless legs syndrome	22.24	13.47	24	16482	20068	79707814
Iron deficiency anaemia	22.22	13.47	27	16479	25645	79702237
Febrile neutropenia	22.21	13.47	10	16496	230989	79496893
Acute kidney injury	22.02	13.47	183	16323	519221	79208661
Complications of transplanted kidney	20.41	13.47	14	16492	6352	79721530
Wheezing	19.72	13.47	61	16445	116603	79611279
Chronic obstructive pulmonary disease	19.69	13.47	50	16456	85369	79642513
Hyperlactacidaemia	19.60	13.47	13	16493	5582	79722300
Haemorrhoids	19.52	13.47	27	16479	29101	79698781
Treatment failure	18.68	13.47	6	16500	170480	79557402
Blood pressure inadequately controlled	18.43	13.47	13	16493	6164	79721718
Hemiparaesthesia	18.11	13.47	5	16501	235	79727647
Aortic valve incompetence	17.41	13.47	15	16491	9515	79718367
Strabismus	17.15	13.47	9	16497	2512	79725370
Choroidal detachment	17.05	13.47	6	16500	630	79727252
Renal cyst	17.01	13.47	18	16488	14714	79713168
Amyloidosis	16.55	13.47	9	16497	2697	79725185
Atrioventricular block	15.94	13.47	17	16489	14024	79713858
Atrioventricular block first degree	15.75	13.47	16	16490	12475	79715407
Inappropriate antidiuretic hormone secretion	15.59	13.47	23	16483	26290	79701592
Vertigo	15.47	13.47	40	16466	69042	79658840
Eosinophilia	15.44	13.47	31	16475	45314	79682568
Hypertensive crisis	15.05	13.47	20	16486	20750	79707132
Hypotension	14.99	13.47	148	16358	440169	79287713
Peripheral swelling	14.78	13.47	101	16405	269516	79458366
Hypervitaminosis	14.76	13.47	3	16503	36	79727846
Metabolic alkalosis	14.69	13.47	10	16496	4479	79723403
Spinal pain	14.66	13.47	17	16489	15375	79712507
Drug abuse	14.20	13.47	8	16498	162683	79565199
Joint abscess	14.10	13.47	5	16501	537	79727345
Blood glucose increased	14.07	13.47	54	16452	114921	79612961
Toxicity to various agents	13.89	13.47	43	16463	421497	79306385
Calcium ionised decreased	13.71	13.47	5	16501	582	79727300
Congenital aortic dilatation	13.63	13.47	3	16503	54	79727828
Nausea	13.47	13.47	275	16231	956921	78770961

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C03BA04	CARDIOVASCULAR SYSTEM DIURETICS LOW-CEILING DIURETICS, EXCL. THIAZIDES Sulfonamides, plain
ATC	C03BB04	CARDIOVASCULAR SYSTEM DIURETICS LOW-CEILING DIURETICS, EXCL. THIAZIDES Sulfonamides and potassium in combination
ATC	C03EA06	CARDIOVASCULAR SYSTEM DIURETICS DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION Low-ceiling diuretics and potassium-sparing agents
FDA PE	N0000175359	Increased Diuresis
FDA EPC	N0000175420	Thiazide-like Diuretic
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D004232	Diuretics
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D045283	Natriuretic Agents
MeSH PA	D049993	Sodium Chloride Symporter Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypertensive disorder	indication	38341003	DOID:10763
Edema	indication	267038008
Pulmonary Edema due to Chronic Heart Failure	indication
Peripheral Edema due to Chronic Heart Failure	indication
Diabetes insipidus	off-label use	15771004	DOID:9409
Calcium renal calculus	off-label use	427649000
Anuria	contraindication	2472002	DOID:2983
Suicidal thoughts	contraindication	6471006
Psoriasis	contraindication	9014002	DOID:8893
Peptic ulcer	contraindication	13200003	DOID:750
Hypercholesterolemia	contraindication	13644009
Chronic disease of respiratory system	contraindication	17097001
Myocardial infarction	contraindication	22298006	DOID:5844
Electroconvulsive therapy	contraindication	23835007
Complete atrioventricular block	contraindication	27885002
Depressive disorder	contraindication	35489007
Hyperuricemia	contraindication	35885006	DOID:1920
Anaphylaxis	contraindication	39579001
Hypokalemia	contraindication	43339004
Diabetes mellitus type 2	contraindication	44054006	DOID:9352
Conduction disorder of the heart	contraindication	44808001
Tear film insufficiency	contraindication	46152009
End stage renal disease	contraindication	46177005	DOID:784
Diabetes mellitus type 1	contraindication	46635009	DOID:9744
Chronic heart failure	contraindication	48447003
Sinus bradycardia	contraindication	49710005
Systemic lupus erythematosus	contraindication	55464009	DOID:9074
Sympathectomy	contraindication	57071006
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004
Cerebrovascular disease	contraindication	62914000	DOID:6713
Ulcerative colitis	contraindication	64766004	DOID:8577
Hypercalcemia	contraindication	66931009	DOID:12678
Hypochloremic alkalosis	contraindication	70134007
Oliguria	contraindication	83128009
Epilepsy	contraindication	84757009	DOID:1826
Cardiogenic shock	contraindication	89138009
Hyponatremia	contraindication	89627008
Gout	contraindication	90560007	DOID:13189
Kidney disease	contraindication	90708001	DOID:557
Liver function tests abnormal	contraindication	166603001
Hypomagnesemia	contraindication	190855004
Asthma	contraindication	195967001	DOID:2841
Acute pancreatitis	contraindication	197456007	DOID:2913
Atrioventricular block	contraindication	233917008	DOID:0050820
Raynaud's phenomenon	contraindication	266261006
Calculus in biliary tract	contraindication	266474003
Pregnancy, function	contraindication	289908002
Severe chronic obstructive pulmonary disease	contraindication	313299006
Surgical procedure	contraindication	387713003
Chronic myocardial ischemia	contraindication	413844008	DOID:3393
First Degree Atrioventricular Heart Block	contraindication
Acutely Decompensated HF Requiring Parenteral Inotropic Therapy	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.63	acidic
pKa2	9.38	acidic
pKa3	13.47	acidic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 40MG MEDOXOMIL;12.5MG	EDARBYCLOR	AZURITY	N202331	Dec. 20, 2011	RX	TABLET	ORAL	7572920	Jan. 7, 2025	TREATMENT OF HYPERTENSION
EQ 40MG MEDOXOMIL;25MG	EDARBYCLOR	AZURITY	N202331	Dec. 20, 2011	RX	TABLET	ORAL	7572920	Jan. 7, 2025	TREATMENT OF HYPERTENSION
EQ 40MG MEDOXOMIL;12.5MG	EDARBYCLOR	AZURITY	N202331	Dec. 20, 2011	RX	TABLET	ORAL	9387249	July 1, 2031	TREATMENT OF HYPERTENSION
EQ 40MG MEDOXOMIL;25MG	EDARBYCLOR	AZURITY	N202331	Dec. 20, 2011	RX	TABLET	ORAL	9387249	July 1, 2031	TREATMENT OF HYPERTENSION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Solute carrier family 12 member 3	Transporter	P55017	S12A3_HUMAN	INHIBITOR			CHEMBL	CHEMBL
Carbonic anhydrase 1	Enzyme	P00915	CAH1_HUMAN		Ki	6.46	CHEMBL
Carbonic anhydrase 4	Enzyme	P22748	CAH4_HUMAN		Ki	6.71	CHEMBL
Carbonic anhydrase 9	Enzyme	Q16790	CAH9_HUMAN		Ki	7.64	CHEMBL
Carbonic anhydrase 12	Enzyme	O43570	CAH12_HUMAN		Ki	8.35	CHEMBL
Carbonic anhydrase 5A, mitochondrial	Enzyme	P35218	CAH5A_HUMAN		Ki	6.04	CHEMBL
Carbonic anhydrase 5B, mitochondrial	Enzyme	Q9Y2D0	CAH5B_HUMAN		Ki	8.05	CHEMBL
Carbonic anhydrase 7	Enzyme	P43166	CAH7_HUMAN		Ki	8.55	CHEMBL
Carbonic anhydrase 3	Enzyme	P07451	CAH3_HUMAN		Ki	4.96	CHEMBL
Carbonic anhydrase 6	Enzyme	P23280	CAH6_HUMAN		Ki	5.87	CHEMBL
Carbonic anhydrase 14	Enzyme	Q9ULX7	CAH14_HUMAN		Ki	5.38	CHEMBL
Carbonic anhydrase 2	Enzyme	P00918	CAH2_HUMAN		Kd	5.56	WOMBAT-PK
Carbonic anhydrase 13	Enzyme		CAH13_MOUSE		Ki	7.82	CHEMBL

External reference:

ID	Source
4017887	VUID
N0000146240	NUI
D00272	KEGG_DRUG
2409	RXNORM
4017887	VANDF
CHEBI:3654	CHEBI
KLT	PDB_CHEM_ID
CHEMBL1055	ChEMBL_ID
CHEMBL255014	ChEMBL_ID
7147	IUPHAR_LIGAND_ID
DB00310	DRUGBANK_ID
4364	MMSL
4432	MMSL
d00192	MMSL
002309	NDDF
387324004	SNOMEDCT_US
57893000	SNOMEDCT_US
D002752	MESH_DESCRIPTOR_UI
C0008294	UMLSCUI
1125	INN_ID
2732	PUBCHEM_CID
Q0MQD1073Q	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	1	0378-0213	TABLET	50 mg	ORAL	ANDA	25 sections
Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	1	0378-0222	TABLET	25 mg	ORAL	ANDA	25 sections
Atenolol and Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	2	0591-5782	TABLET	25 mg	ORAL	ANDA	18 sections
Atenolol and Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	2	0591-5783	TABLET	25 mg	ORAL	ANDA	18 sections
Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6900	TABLET	25 mg	ORAL	ANDA	21 sections
ATENOLOL AND CHLORTHALIDONE	HUMAN PRESCRIPTION DRUG LABEL	2	10135-733	TABLET	25 mg	ORAL	ANDA	21 sections
ATENOLOL AND CHLORTHALIDONE	HUMAN PRESCRIPTION DRUG LABEL	2	10135-734	TABLET	25 mg	ORAL	ANDA	21 sections
Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	1	16714-128	TABLET	25 mg	ORAL	ANDA	16 sections
Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	1	16714-128	TABLET	25 mg	ORAL	ANDA	16 sections
Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	1	16714-129	TABLET	50 mg	ORAL	ANDA	16 sections
Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	1	16714-129	TABLET	50 mg	ORAL	ANDA	16 sections
Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	1	16714-800	TABLET	25 mg	ORAL	ANDA	21 sections
Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	1	16714-801	TABLET	50 mg	ORAL	ANDA	21 sections
Atenolol and Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	2	16714-936	TABLET	25 mg	ORAL	ANDA	16 sections
Atenolol and Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	2	16714-936	TABLET	25 mg	ORAL	ANDA	16 sections
Atenolol and Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	2	16714-937	TABLET	25 mg	ORAL	ANDA	16 sections
Atenolol and Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	2	16714-937	TABLET	25 mg	ORAL	ANDA	16 sections
Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	1	21695-671	TABLET	25 mg	ORAL	ANDA	24 sections
Atenolol and Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	2	21695-743	TABLET	25 mg	ORAL	ANDA	18 sections
Atenolol and Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	2	21695-744	TABLET	25 mg	ORAL	ANDA	18 sections
Chlorthalidone	Human Prescription Drug Label	1	27241-216	TABLET	25 mg	ORAL	ANDA	20 sections
Chlorthalidone	Human Prescription Drug Label	1	27241-217	TABLET	50 mg	ORAL	ANDA	20 sections
Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	1	29300-333	TABLET	25 mg	ORAL	ANDA	19 sections
Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	1	29300-333	TABLET	25 mg	ORAL	ANDA	19 sections
Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	1	29300-334	TABLET	50 mg	ORAL	ANDA	19 sections
Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	1	29300-334	TABLET	50 mg	ORAL	ANDA	19 sections
Atenolol and Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	2	29300-400	TABLET	25 mg	ORAL	ANDA	17 sections
Atenolol and Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	2	29300-401	TABLET	25 mg	ORAL	ANDA	17 sections
Atenolol and Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	2	33261-942	TABLET	25 mg	ORAL	ANDA	18 sections
Atenolol and Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	2	43353-149	TABLET	25 mg	ORAL	ANDA	18 sections